Medical Journals

Vaccinations with Recombinant Variants of Aspergillus Fumigatus Allergen Asp F 3 Protect Mice Against Invasive Aspergillosis.

Authors:
  • Ito James I
  • Lyons Joseph M
  • Hong Teresa B
  • Tamae Daniel
  • Liu Yi-Kuang
  • Wilczynski Sharon P
  • Kalkum Markus

From: Immunology Division, City of Hope National Medical Center and Beckman Research Institute, 1500 E. Duarte Road, Duarte, CA 91010-3000, USA.

Infection and immunity

  • Publish Date: Sep 2006
  • ISSN: 0019-9567
  • Volume: 74
  • Issue: 9
  • Pages: 5075-84
  • Medium: Print
  • Language: English
  • Citation (JAMA): Ito James I, Lyons Joseph M, Hong Teresa B, et al. Vaccinations with Recombinant Variants of Aspergillus Fumigatus Allergen Asp F 3 Protect Mice Against Invasive Aspergillosis.. Infect. Immun. Sep 2006;74:5075-84

Abstract

A vaccine that effectively protects immunocompromised patients against invasive aspergillosis is a novel approach to a universally fatal disease. Here we present a rationale for selection and in vivo testing of potential protein vaccine candidates, based on the modification of an immunodominant fungal allergen for which we demonstrate immunoprotective properties. Pulmonary exposure to viable Aspergillus fumigatus conidia as well as vaccination with crude hyphal extracts protects corticosteroid-immunosuppressed mice against invasive aspergillosis (J. I. Ito and J. M. Lyons, J. Infect. Dis. 186:869-871, 2002). Sera from the latter animals contain antibodies with numerous and diverse antigen specificities, whereas sera from conidium-exposed mice contain antibodies predominantly against allergen Asp f 3 (and some against Asp f 1), as identified by mass spectrometry. Subcutaneous immunization with recombinant Asp f 3 (rAsp f 3) but not with Asp f 1 was protective. The lungs of Asp f 3-vaccinated survivors were free of hyphae and showed only a patchy low-density infiltrate of mononuclear cells. In contrast, the nonimmunized animals died with invasive hyphal elements and a compact peribronchial infiltrate of predominantly polymorphonuclear leukocytes. Three truncated versions of rAsp f 3, spanning amino acid residues 15 to 168 [rAsp f 3(15-168)], 1 to 142, and 15 to 142 and lacking the known bipartite sequence required for IgE binding, were also shown to be protective. Remarkably, vaccination with either rAsp f 3(1-142) or rAsp f 3(15-168) drastically diminished the production of antigen-specific antibodies compared to vaccination with the full-length rAsp f 3(1-168) or the double-truncated rAsp f 3(15-142) version. Our findings point to a possible mechanism in which Asp f 3 vaccination induces a cellular immune response that upon infection results in the activation of lymphocytes that in turn enhances and/or restores the function of corticosteroid-suppressed macrophages to clear fungal elements in the lungs.

Mesh Headings (Keywords): Allergens, Amino Acid Sequence, Animals, Antibodies, Fungal, Aspergillosis, Aspergillus fumigatus, Fungal Vaccines, Hyphae, Immunity, Cellular, Lung, Lymphocytes, Mice, Recombinant Proteins, Sequence Deletion


Check for Full Text / PubMed Unique Identifier (PMID): 16926399


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.